Pamidronate to Treat Osteogenesis Imperfecta in Children
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteogenesis Imperfecta
Intervention: Pamidronate (Aredia) (Drug)
Phase: Phase 3
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official(s) and/or principal investigator(s):
Joan C Marini, M.D., Principal Investigator, Affiliation: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
This study will evaluate the effect of pamidronate a drug that decreases bone resorption
(breakdown) on osteogenesis imperfecta. This is a genetic disorder of collagen, the major
protein in bone. The abnormal collagen causes weak bones, and children with severe
osteogenesis imperfecta sustain many fractures throughout their lives. They also have
growth deficiency, curvature of the spine, crumbling teeth, hearing loss, easy bruising and
heart and lung problems. The study will compare bone density, quality and strength, final
adult height, trunk height, and functional ability in children who receive 1) pamidronate
every 3 months, 2) pamidronate every 3 months + growth hormone injections, 3) pamidronate
every 6 months, or 4) pamidronate every 6 months + growth hormone injections.
Children 2 years of age and older with severe osteogenesis imperfecta (types III and IV) may
be eligible for this study. Those enrolled will be randomly assigned to groups according to
age; children two to four years of age will be randomly assigned to receive pamidronate
every 3 or every 6 months. Children four years of age and older may participate in the
growth hormone treatment groups. These children will continue on growth hormone until they
reach their adult height or fail to grow as much as would be expected for someone on growth
Patients will be followed in the clinic every 3 months for a history, physical examination,
X-rays, blood tests, and measurements (weight, head circumference, and bone lengths).
Children will receive a 3 to 4 hour infusion of pamidronate through an intravenous catheter
(thin flexible tube placed in a vein) once a day for 3 days each visit. (Once inserted, the
catheter is left in place to avoid multiple needle sticks for administering the drug and
collecting blood samples.) Children who are taking growth hormone will be given the drug at
the first treatment visit. At that time, the accompanying parent will be instructed on how
to mix the drug and give injections. The child receives an injection 6 days a week (Sunday
Official title: A Trial of Pamidronate in Children With Osteogenesis Imperfecta
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Bone mineral density.
Muscle and motor function
Vertebral area and height.
Osteogenesis imperfecta is an inherited disorder of connective tissue in which affected
individuals synthesize abnormal type I collagen. This results in the formation of abnormal
bone matrix and a predisposition to bony fractures. Many unsuccessful attempts have been
made to increase the bone mineral density of these individuals in the hope that this will
improve the strength of their bones and result in a decreased fracture rate.
Bisphosphonates are synthetic analogs of pyrophosphate which have an affinity for
hydroxyapatite. These drugs act primarily on osteoclasts, impairing the development of
immature osteoclasts and the function of mature osteoclasts, as well as depressing chemical
signaling to adjacent cells, resulting in a shift in the balance of deposition and
resorption in bone. Conditions for which bisphosphonates are being used in children include
four broad categories, 1) a primary defect in bone mineralization 2) bone matrix
abnormalities 3) bone abnormalities due to systemic disease or the effects of treatment of
systemic disease or 4) significant soft tissue calcification with no bone abnormality.
Pamidronate, an aminobisphosphonate, is a potent inhibitor of bone resorption. The purpose
of this protocol is to evaluate the effectiveness of pamidronate in children with types III
and IV osteogenesis imperfecta when the cycle time is varied. We plan to compare children
treated with pamidronate on an every-three-month infusion cycle to children treated every
six months with the same dose per infusion. We also plan to continue to compare children
treated with pamidronate and growth hormone to children treated with pamidronate alone.
Minimum age: N/A.
Maximum age: 16 Years.
- INCLUSION CRITERIA:
Children enrolled in this study will be limited to those with Sillence types III and IV
OI, as determined by clinical and genetic criteria.
Most of the children who will be included in this study are already enrolled in the
protocols Evaluation and Intervention for Ambulation, Growth, and Basilar Invagination in
Osteogenesis Imperfecta (97-CH-0064) and Growth Hormone Therapy in Osteogenesis Imperfecta
Screening of candidates will be based on telephone interviews with a parent, and referral
records to include: AP and lateral radiographs of the lower extremities and spine, and
family, developmental, fracture and medical history. An NIH clinical screening evaluation
will be performed for those children who appear to have a history consistent with OI under
protocol 04-CH-0077, Screening of and Diagnosis of Patients with Connective Tissue
Disorder . Patients admitted for this screening visit who are less than four years of
age as well as those older than 4 years of age but not meeting the criteria for inclusion
in the growth hormone protocol, protocol 92-CH-0034, will be considered for enrollment in
protocol 97-CH-0064 (Evaluation and Intervention for Ambulation, Growth and Basilar
Invagination in OI), those older than four years who meet the criteria will be considered
for co-enrollment in protocol 92-CH-0034.
The inclusion criteria for protocol 92-CH-0034 are as follows: patients must have a
clinical/biochemical diagnosis of osteogenesis imperfecta types III or IV, height less
than third percentile for age, and radiological evidence that long bone epiphyses have not
Patients are excluded from protocol 92-CH-0034 if they have scoliosis of greater than 40
degrees unless scoliosis has been stable over the past two years, or evidence of severe
Patients with previous exposure to bisphosphonates in outside trials will be considered
for participation in this trial.
Inability to comply with the visit schedule, maintenance of the physical therapy program,
and ability to administer and comply with GH injections are central to our analysis of the
outcomes of this study. Failure to comply with these conditions will constitute exclusion
Patients that have had or will have surgery to place instrumentation in the spine (i. e.
result of spine fusion).
Locations and Contacts
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
NIH Clinical Center Detailed Web Page
Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr. 1988;35:391-426. Review.
Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N Engl J Med. 1984 Aug 9;311(6):376-86. Review.
Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet. 1993 Jan 15;45(2):261-4.
Starting date: June 2000
Last updated: March 19, 2015